A B S T R A C T PurposeAll patients in phase I trials do not have equivalent susceptibility to serious drug-related toxicity (SDRT). Our goal was to develop a nomogram to predict the risk of cycle-one SDRT to better select appropriate patients for phase I trials. Patients and MethodsThe prospectively maintained database of patients with solid tumor enrolled onto Cancer Therapeutics Evaluation Program-sponsored phase I trials activated between 2000 and 2010 was used. SDRT was defined as a grade Ն 4 hematologic or grade Ն 3 nonhematologic toxicity attributed, at least possibly, to study drug(s). Logistic regression was used to test the association of candidate factors to cycle-one SDRT. A final model, or nomogram, was chosen based on both clinical and statistical significance and validated internally using a bootstrapping technique and externally in an independent data set. ResultsData from 3,104 patients enrolled onto 127 trials were analyzed to build the nomogram. In a model with multiple covariates, Eastern Cooperative Oncology Group performance status, WBC count, creatinine clearance, albumin, AST, number of study drugs, biologic study drug (yes v no), and dose (relative to maximum administered) were significant predictors of cycle-one SDRT. All significant factors except dose were included in the final nomogram. The model was validated both internally (bootstrap-adjusted concordance index, 0.60) and externally (concordance index, 0.64). ConclusionThis nomogram can be used to accurately predict a patient's risk for SDRT at the time of enrollment. Excluding patients at high risk for SDRT should improve the safety and efficiency of phase I trials.
PurposePatients who do not complete one cycle of therapy on Phase I trials for reasons other than dose limiting toxicity (DLT) are considered inevaluable for toxicity and must be replaced.MethodsIndividual records from patients enrolled to NCI-sponsored Phase I trials activated between 2000 and 2010 were used. Early discontinuation was defined as the failure to begin cycle 2 for reasons other than a DLT during cycle 1. A multinomial logistic regression with a 3-level nominal outcome (early discontinuation, DLT during cycle 1, and continuation to cycle 2) was used with continuation to cycle 2 serving as the reference category. The final model was used to create two risk scores. An independent external cohort was used to validate these models.ResultsData from 3079 patients on 127 Phase I trials were analyzed. ECOG performance status (1, ≥ 2, two-sided P = .0315 and P = .0007), creatinine clearance (<60 ml/min, P = .0455), alkaline phosphatase (>2.5xULN, P = .0026), AST (>ULN, P = .0076), hemoglobin (<10 g/dL, P < .0001), albumin (< 3.5 g/dL, P < .0001), and platelets (<400x109/L, P = .0732) were predictors of early discontinuation. The c-index of the final model was 0.63.ConclusionKnowledge of risk factors for early treatment discontinuation in conjunction with clinical judgment can help guide Phase I patient selection.
Background Phase I studies rely on investigators to accurately attribute of adverse events as related or unrelated to study drug. This information is ultimately used to help establish a safe dose. Patterns of physician attribution in the Phase I setting have not been widely studied and assessing the accuracy of attribution is complicated by the lack of a gold standard. We examined dose-toxicity relationships as a function of attribution and toxicity category to evaluate for evidence of toxicity misattribution. Methods Individual patient records from 38 Phase I studies activated between 2000-2010 were used. Dose was defined as percent of maximum dose administered on each study. Relationships between dose and patient-level toxicity were explored graphically and with logistic regression. All p-values were two-sided. Results 11,909 toxicities from 1,156 patients were analyzed. Unrelated toxicity was not associated with dose (p=0.0920 for grade ≥3, p=0.4194 for grade ≥1) while related toxicity increased with dose (p<0.0001, both grade ≥3 and ≥1). Similar results were observed across toxicity categories. In the 5-tier system, toxicities attributed as ‘possibly’, ‘probably’, or ‘definitely’ related were associated with dose (all p<0.0001) while toxicities attributed as ‘unlikely’, or ‘unrelated’ were not (all p>0.1). Conclusions Reassuringly, we did not observe an association between unrelated toxicity rate and dose, an association which could only have been explained by physician misattribution. Our findings also confirmed our expectation that related toxicity rate increases with dose. Our analysis supports simplifying attribution to a 2-tier system by collapsing ‘possibly’, ‘probably’, and ‘definitely’ related.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.